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RV

:   right ventricular

ARVC

:   arrhythmogenic right ventricular cardiomyopathy

ARVD

:   arrhythmogenic right ventricular dysplasia

PSAX

:   parasternal short axis

PLAX

:   parasternal long axis

RVOT

:   right ventricular outflow tract

RV‐FAC

:   right ventricular fractional area change

LV

:   left ventricular

TFC

:   task force criteria

LVEF

:   left ventricular ejection fraction

PVC

:   premature ventricular complexes

PKP2

:   plakophillin‐2

DSG2

:   desmoglein‐2

DSC2

:   desmocollin‐2

DSP

:   desmoplakin

JUP

:   plakoglobin

TMEM43

:   transmembrane protein 43

PLN

:   phospholamban

DICOM

:   Digital Imaging and Communications in Medicine

RBBB

:   right bundle‐branch block

SCD

:   sudden cardiac death

VT

:   ventricular tachycardia

Clinical PerspectiveWhat Is New?Echocardiographic right ventricular strain and strain rate at baseline are associated with the rate of future progression of structural abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy.What Are the Clinical Implications?Patients with suspected arrhythmogenic right ventricular cardiomyopathy and abnormal baseline right ventricular strain or strain rate could be at higher risk of disease progression and may warrant closer observation.

Introduction {#jah35005-sec-0008}
============

Arrhythmogenic right ventricular (RV) cardiomyopathy (ARVC) is a genetic disease characterized pathologically by fibrofatty replacement of the myocardium and clinically by ventricular dysfunction and arrhythmias.[1](#jah35005-bib-0001){ref-type="ref"}, [2](#jah35005-bib-0002){ref-type="ref"} Since the first major description of the disease,[3](#jah35005-bib-0003){ref-type="ref"} attention has been devoted to establishing diagnostic criteria,[4](#jah35005-bib-0004){ref-type="ref"} identifying genotypes,[5](#jah35005-bib-0005){ref-type="ref"} predicting prognosis,[6](#jah35005-bib-0006){ref-type="ref"}, [7](#jah35005-bib-0007){ref-type="ref"}, [8](#jah35005-bib-0008){ref-type="ref"} and developing guidelines for management.[7](#jah35005-bib-0007){ref-type="ref"}, [8](#jah35005-bib-0008){ref-type="ref"} Prognostication of ARVC is challenging because clinical manifestations typically become apparent between the second and fourth decades of life.[8](#jah35005-bib-0008){ref-type="ref"}, [9](#jah35005-bib-0009){ref-type="ref"}, [10](#jah35005-bib-0010){ref-type="ref"} In addition, substantial interpatient variability in structural progression of disease has been noted.[11](#jah35005-bib-0011){ref-type="ref"} Therefore, accurate and reliable prediction of structural progression is an important area of clinical interest, as presenting events can be fatal. Noninvasive measures determined by the 2010 task force criteria (TFC) include structural and functional parameters for diagnosis of ARVC by echocardiography including RV outflow tract (RVOT) dimension and RV fractional area change (RV‐FAC).[4](#jah35005-bib-0004){ref-type="ref"} Changes to these imaging parameters have been used to identify and follow disease progression.[11](#jah35005-bib-0011){ref-type="ref"} Echocardiography has emerged as an ideal modality because it is noninvasive, widely available,[12](#jah35005-bib-0012){ref-type="ref"} and safe for use in patients defibrillators, as is common in ARVC.

Echocardiographic myocardial strain has emerged as a principal method for the quantification of subclinical left ventricular (LV) dysfunction in a variety of clinical settings,[13](#jah35005-bib-0013){ref-type="ref"} including chemotoxicity[14](#jah35005-bib-0014){ref-type="ref"} and ischemic heart disease.[15](#jah35005-bib-0015){ref-type="ref"} The role of echocardiographic strain in evaluating RV dysfunction in patients with ARVC is not fully elucidated, although several studies have indicated a possible role for this technique. Prior studies report reduced RV free wall strain and strain rate in patients with ARVC compared with measurements in healthy controls.[16](#jah35005-bib-0016){ref-type="ref"}, [17](#jah35005-bib-0017){ref-type="ref"}, [18](#jah35005-bib-0018){ref-type="ref"}, [19](#jah35005-bib-0019){ref-type="ref"}, [20](#jah35005-bib-0020){ref-type="ref"} Limited data have evaluated the utility of various echocardiographic parameters in ARVC for predicting disease progression over time. In one study, variability in RV and LV contraction duration was associated with greater arrhythmia risk.[21](#jah35005-bib-0021){ref-type="ref"} A recent study in first‐degree relatives of patients with ARVC found abnormal RV deformation in the subtricuspid region to be associated with disease progression.[22](#jah35005-bib-0022){ref-type="ref"} However, no studies have systematically characterized the role of traditional and novel measures of RV dysfunction as they relate to ARVC disease progression. Moreover, further characterization of the relationship between RV strain and structural progression over time in ARVC would be beneficial for risk stratification.

The purpose of this study was to evaluate echocardiographic free‐wall longitudinal strain of the RV as a predictor of progression of structural disease in ARVC using data from patients who underwent serial echocardiograms enrolled in the Johns Hopkins ARVC registry. We hypothesized that worse peak RV strain and strain rate would be significantly associated with progression of disease, as defined by increasing RVOT dimension and decreased RV‐FAC.[4](#jah35005-bib-0004){ref-type="ref"}

Methods {#jah35005-sec-0009}
=======

Study Population {#jah35005-sec-0010}
----------------

The study population consisted of 40 patients with ARVC from the Johns Hopkins arrhythmogenic right ventricular dysplasia/cardiomyopathy registry (<http://ARVD.com>). All patients were diagnosed with ARVC and fulfilled the 2010 task force criteria.[4](#jah35005-bib-0004){ref-type="ref"} To be included in this study, patients must have undergone at least 2 separate echocardiograms \>6 months apart that were digitally available and of sufficient quality for analysis. The first and last available examinations were used for analysis, and the first exam was considered the baseline echocardiogram. The study was approved by the Johns Hopkins Medicine institutional review boards, and patients in the Johns Hopkins University arrhythmogenic right ventricular dysplasia/cardiomyopathy registry provided written informed consent. Participants did not receive compensation for this study. The data that support the findings of this study are available from the corresponding author on reasonable request.

Clinical Characterization {#jah35005-sec-0011}
-------------------------

Fulfillment of TFC[4](#jah35005-bib-0004){ref-type="ref"} was assessed for each patient, as similarly performed by Mast et al.[11](#jah35005-bib-0011){ref-type="ref"} All patients had complete transthoracic echocardiograms including dedicated RV apical views. LV ejection fraction was calculated on 2‐dimensional parasternal long‐axis (PLAX) images using the modified Quinones formula.[23](#jah35005-bib-0023){ref-type="ref"} Cardiac magnetic resonance was performed per standard ARVC protocols described elsewhere and was used only to assess fulfillment of TFC structural criteria.[24](#jah35005-bib-0024){ref-type="ref"}

All participants had undergone 12‐lead ECG recordings as part of assessment of TFC. ECG recordings were analyzed for fulfillment of TFC,[4](#jah35005-bib-0004){ref-type="ref"} including depolarization criteria (ε waves and terminal activation duration ≥55 ms) and repolarization criteria (precordial T‐wave inversion, V~1~--V~6~). In addition, signal‐averaged ECG was evaluated for the presence of late potentials. History of arrhythmias (nonsustained or sustained ventricular tachycardia of criteria‐defined axis and morphology) was also noted. Holter monitors were evaluated for premature ventricular complex count and were considered abnormal if \>500 was observed in 24 hours, per the TFC.

All index patients also underwent genetic testing by molecular genetic screening of 5 ARVC‐associated desmosomal genes (*PKP2* \[plakophillin‐2\], *DSG2* \[desmoglein‐2\], *DSC2* \[desmocollin‐2\], *DSP* \[desmoplakin\], and *JUP* \[plakoglobin\]), as well as nondesmosomal genes (*TMEM43* \[transmembrane protein 43\] and *PLN* \[phospholamban\]).

Assessment of Structural Progression {#jah35005-sec-0012}
------------------------------------

Echocardiograms performed at baseline and follow‐up were exported from Synapse Cardiovascular (FUJIFILM Medical Systems) in DICOM (Digital Imaging and Communications in Medicine) format and analyzed using Image‐Arena v4 (TomTec Imaging Systems), a vendor‐neutral imaging platform.

Measurements were obtained for proximal RVOT dimensions in both PLAX and parasternal short‐axis (PSAX) views during end‐diastole, as shown in Figure [1](#jah35005-fig-0001){ref-type="fig"}. RV‐FAC was assessed as described in the TFC[4](#jah35005-bib-0004){ref-type="ref"} as the percentage of RV area decrease between diastole and systole obtained on apical imaging. All echocardiograms were analyzed by a single operator (S.W.) to exclude interobserver variability, and measurements were performed blinded to clinical data.

![Measurement of right ventricular outflow tract (RVOT) dimensions.\
Measurement of proximal (Prox) RVOT dimensions on the parasternal long‐axis (PLAX) and short‐axis (PSAX) views.](JAH3-9-e015016-g001){#jah35005-fig-0001}

Structural progression was assessed by calculating the change in these echocardiographic parameters between the baseline and follow‐up studies. These changes were normalized as yearly and 5‐year rates of change, and patients were subsequently grouped into quartiles by rate of change. Patients were characterized as *progressors* or *nonprogressors* for each variable; progression was defined as an increase in PSAX RVOT size, increase in PLAX RVOT size, and decrease in RV‐FAC.

Assessment of Strain and Strain Rate {#jah35005-sec-0013}
------------------------------------

RV free‐wall peak longitudinal systolic strain and strain rate were measured on DICOM images of an RV‐focused apical 4‐chamber view by endocardial speckle‐tracking using the 2D Cardiac Performance Analysis module of Image‐Arena. All available cardiac cycles were examined, and the best‐quality clip with optimal tracking was chosen. The peak values of free‐wall strain and strain rate were defined as the deepest points of the respective curves (Figure [2](#jah35005-fig-0002){ref-type="fig"}). The exact time of peak may vary but is generally around end systole for strain and early systole for strain rate. Furthermore, the peaks may not occur at the same time for the free wall and septum; however, only free‐wall values were used in our analysis, and septal strain values were excluded. LV endocardial peak longitudinal systolic strain was measured using the AutoStrain package on similarly selected cycles with optimal tracking, where the endocardium was automatically recognized and fine‐tuned manually at end diastole (first frame after mitral valve closure) and end systole (first frame after aortic valve closure). A sample image of RV strain on a patient with ARVC is shown in Figure [2](#jah35005-fig-0002){ref-type="fig"}. A similar technique is described by Hamada‐Harimura et al.[25](#jah35005-bib-0025){ref-type="ref"}

![Representative image of right ventricular strain measurement.\
A sample image from TomTec Image‐Arena is shown. Software detected the myocardial--endocardial interface and was manually adjusted by an operator to ensure accuracy. The software then calculated strain and strain rate.](JAH3-9-e015016-g002){#jah35005-fig-0002}

Statistical Analysis {#jah35005-sec-0014}
--------------------

Continuous data are presented as mean±SD or median with interquartile range. Categorical variables are presented as counts and percentages. A 2‐sided *P*\<0.05 was considered significant. Differences between baseline and follow‐up echocardiographic measurements were compared using paired *t* tests for continuous variables and χ^2^ tests for categorical variables. Multivariable logistic regression (for risk of progression) and linear regression (for quartile of progression rate) adjusting for age and sex were used to assess the relationship between baseline RV strain and strain rate and structural progression. This was done separately for RVOT PSAX, RVOT PLAX, and RV‐FAC. Statistical analysis was performed using Stata v14.2 (StataCorp).

Results {#jah35005-sec-0015}
=======

Clinical characteristics for the patient population are shown in Table [1](#jah35005-tbl-0001){ref-type="table"}. All 40 participants fulfilled the TFC for definite ARVC. There were 29 probands and 11 affected family members; 21 patients (53%) were women. Mean age was 35.2±12.6 years at baseline, and median time to follow‐up echocardiogram was 3.6 years (interquartile range: 1.3--6.8 years). Minimum age at baseline was 19 years, and maximum age was 73 years. A pathogenic or likely pathogenic variant was identified in 65% of the study population. Variants in *PKP2* were most common (n=21, 53%). From echocardiography, 23 patients (58%) met major criteria at baseline, whereas 29 patients (73%) met major criteria at follow‐up. LV ejection fraction was 58±7.3% at baseline and 56±10.9% at follow‐up (*P*=0.035). LV global longitudinal peak systolic strain was relatively stable during follow‐up (−20.1% to −19.3%; *P*=0.253).

###### 

Clinical Characteristics of Study Population

  Characteristic                                                     Baseline Exam, n (%)   Follow‐Up Exam[\*](#jah35005-note-0004){ref-type="fn"}   *P* Value
  ------------------------------------------------------------------ ---------------------- -------------------------------------------------------- -----------
  Demographics                                                                                                                                       
  Age, y, mean (SD)                                                  35.2 (±12.6)           39.7 (±12.3)                                             ...
  Male                                                               19 (48)                ...                                                      ...
  White                                                              40 (100)               ...                                                      ...
  Probands                                                           29 (73)                ...                                                      ...
  ICD                                                                34 (85)                37 (93)                                                  0.288
  Genetics                                                                                                                                           
  Pathogenic mutation                                                26 (65)                ...                                                      ...
  *PKP2*                                                             21 (53)                ...                                                      ...
  *DSG2*                                                             2 (5)                  ...                                                      ...
  *DSP*                                                              0 (0)                  ...                                                      ...
  *DSC2*                                                             1 (3)                  ...                                                      ...
  *PLN*                                                              1 (3)                  ...                                                      ...
  *SCN5A* (non‐TFC mutation)                                         1 (3)                  ...                                                      ...
  No pathogenic mutation                                             14 (35)                ...                                                      ...
  TFC                                                                                                                                                
  Structural (by echocardiography)                                                                                                                   
  Major                                                              23 (58)                29 (73)                                                  0.160
  Minor                                                              3 (8)                  1 (2)                                                    0.305
  Depolarization                                                                                                                                     
  Epsilon waves (major)                                              5 (13)                 8 (20)                                                   0.363
  Depolarization minor TFC[†](#jah35005-note-0005){ref-type="fn"}    23 (58)                23 (58)                                                  1.000
  Terminal activation duration ≥55 ms                                15 (38)                20 (50)                                                  0.294
  Repolarization                                                                                                                                     
  TWI in V1--V3 (major)                                              31 (78)                33 (83)                                                  0.420
  TWI V1--V2 (minor)                                                 35 (88)                35 (88)                                                  0.754
  TWI V4--V6 (minor)                                                 6 (15)                 9 (23)                                                   0.390
  TWI V1--V4 in presence of RBBB (minor)                             5 (13)                 6 (15)                                                   0.745
  Arrhythmias                                                                                                                                        
  VT, superior major axis (major)                                    8 (20)                 9 (23)                                                   0.834
  VT, inferior or unknown axis (minor)                               22 (55)                25 (63)                                                  0.479
  PVC \>500 in 24 h (minor)[‡](#jah35005-note-0006){ref-type="fn"}   29 (73)                34 (85)                                                  0.815
  Family history                                                                                                                                     
  Pathogenic ARVC mutation carrier                                   26 (65)                ...                                                      ...
  ARVC confirmed in first‐degree relative                            13 (33)                ...                                                      ...
  ARVC confirmed, second‐degree relative                             2 (5)                  ...                                                      ...
  SCD \<35 in first‐degree relative owed to ARVC                     4 (10)                 ...                                                      ...

*P* value was obtained after performing χ^2^ analysis. ARVC indicates arrhythmogenic right ventricular cardiomyopathy; *DSC2*, desmocollin‐2; *DSG2*, desmoglein‐2; *DSP*, desmoplakin; ICD, implantable cardioverter‐defibrillator; *PKP2*, plakophillin‐2; *PLN*, phospholamban; PVC, premature ventricular complexes; RBBB, right bundle‐branch block; SCN5A, sodium channel gene alpha subunit; TWI, T wave inversions; SCD, sudden cardiac death; TFC, task force criteria; and VT, ventricular tachycardia.

Empty cells indicate no change from baseline.

Depolarization minor criteria were scored if terminal activation duration was \>55 ms on ECG or late potentials by signal‐averaged ECG.

Holter monitoring had been performed on only 33 patients at baseline and 38 patients at follow‐up.

Between baseline and follow‐up studies, mean RVOT PSAX increased from 36.2 to 38.5 mm (*P*=0.022) with structural progression (increase in size) in 23 patients (60%); mean RVOT PLAX increased from 36.1 to 39.2 mm (*P*=0.001) with progression in 25 patients (67%); and mean RV‐FAC was relatively unchanged, decreasing from 31.6% to 30.6% (*P*=0.331) with 21 patients (52%) classified as progressed. Baseline age, sex, LV ejection fraction, RV‐FAC, RV basal diameter, and fulfillment of major structural TFC by echocardiography were compared according to progression status, and results are summarized in Table [2](#jah35005-tbl-0002){ref-type="table"}. Patients who exhibited progression by RVOT PSAX overall had lower RV‐FAC (28.5±9.6% versus 38.1±6.6%, *P*=0.002), larger RV basal diameters (4.6±0.88 versus 3.9±0.42 cm, *P*=0.005), and a greater percentage of patients meeting major structural criteria by echocardiography (74% versus 27%, *P*=0.004) at baseline compared with patients who did not progress by RVOT PSAX. In addition, progressors by RVOT PSAX tended to be men, compared with nonprogressors (61% versus 27%, *P*=0.039). Patients who exhibited progression (decrease) in RV‐FAC had significantly greater RV‐FAC measurements at baseline (35.2±9.7 versus 27.7±8.6, *P*=0.014) compared with patients who did not progress by RV‐FAC.

###### 

Comparison of Demographics and LVEF by Progression Status

                                                                          RVOT PSAX Progression   RVOT PLAX Progression   RV‐FAC Progression                                                           
  ----------------------------------------------------------------------- ----------------------- ----------------------- -------------------- ----------- ----------- ------- ----------- ----------- -------
  Age, y, mean±SD                                                         34.5±12.5               33.6±10.7               0.825                36.2±12.9   31.0±7.7    0.212   34.7±11.7   35.8±13.8   0.791
  Male (%)                                                                14 (61)                 4 (27)                  0.039                11 (44)     6 (50)      0.732   8 (38)      11 (58)     0.210
  LVEF, %, mean±SD                                                        57.6±8.2                60.8±5.0                0.187                58.2±6.9    60.0±8.3    0.504   57.0±7.3    60.1±7.2    0.184
  Baseline RV‐FAC, %, mean±SD                                             28.5±9.6                38.1±6.6                0.002                32.1±9.3    33.4±10.6   0.708   35.2±9.7    27.7±8.6    0.014
  Baseline RV basal diameter, cm, mean±SD                                 4.6±0.88                3.9±0.42                0.005                4.3±0.79    4.2±0.90    0.703   4.4±0.66    4.4±1.0     0.969
  Major structural TFC satisfied by echocardiography at baseline, n (%)   17 (74)                 4 (27)                  0.004                16 (64)     4 (33)      0.080   12 (57)     11 (58)     0.962

Baseline age, sex, LVEF, RV‐FAC, RV basal diameter, and fulfillment of major structural TFC by echocardiography were compared across progression status. *P* values were calculated using *t* tests (age, LVEF, RV‐FAC, RV basal diameter) and χ^2^ analysis (sex, major structural TFC by echocardiography). LVEF indicates left ventricular ejection fraction; PLAX, parasternal long axis; PSAX, parasternal short axis; RV, right ventricular; RV‐FAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; and TFC, Task Force Criteria.

Table [3](#jah35005-tbl-0003){ref-type="table"} shows the association of baseline RV strain and strain rate with the risk of structural progression and across quartiles of 5‐year rate of change for each of the 3 parameters (adjusted for age and sex). Overall, both RV strain and strain rate were significantly associated with the likelihood of future structural progression and the rate of change of PSAX RVOT and PLAX RVOT dimensions. Patients with more negative strain (eg, −22.7% for PSAX quartile 1) or strain rate were less likely to progress, whereas less negative numbers (eg, −14.5% for PSAX quartile 4) were associated with a faster rate of structural progression. No significant differences in strain or strain rate were seen between structural progressors and nonprogressors or by quartile of rate of change according to RV‐FAC. A comparison of distribution of baseline RV strain across each quartile is shown in Figure [3](#jah35005-fig-0003){ref-type="fig"}.

###### 

Association of Baseline RV Strain and Strain Rate With Risk and Rate of Structural Progression by PSAX‐RVOT, PLAX‐RVOT, and RV‐FAC

                                 Structural Progression   Quartile of 5‐y Rate of Change (1=Best, 4=Worst)                                                               
  ------------------------------ ------------------------ -------------------------------------------------- ------- ------------ ------------ ------------ ------------ -------
  PSAX RVOT                                                                                                                                                              
  RV strain, %, mean±SD          −15.4±4.5                −22.7±3.9                                          0.007   −22.7±3.6    −20.4±5.4    −15.5±4.5    −14.5±4.8    0.001
  RV strain rate, 1/s, mean±SD   −0.64±0.21               −0.97±0.23                                         0.003   −0.91±0.18   −0.90±0.31   −0.68±0.28   −0.59±0.17   0.011
  PLAX RVOT                                                                                                                                                              
  RV strain, %, mean±SD          −17.3±4.9                −20.6±6.6                                          0.160   −20.9±7.0    −19.5±4.3    −18.3±3.7    −14.6±5.5    0.011
  RV strain rate, 1/s, mean±SD   −0.71±0.25               −0.91±0.27                                         0.043   −0.87±0.16   −0.90±0.34   −0.76±0.26   −0.57±0.22   0.008
  RV‐FAC                                                                                                                                                                 
  RV strain, %, mean±SD          −18.6±5.7                −16.8±6.4                                          0.505   −15.9±7.0    −17.0±6.1    −18.9±6.7    −19.2±4.2    0.219
  RV strain rate, 1/s, mean±SD   −0.79±0.32               −0.71±0.24                                         0.497   −0.63±0.28   −0.74±0.22   −0.84±0.40   −0.78±0.20   0.254

RV strain and strain rate are compared between progressors and nonprogressors and across quartiles of 5‐y rate of change. PLAX indicates parasternal long axis; PSAX, parasternal short axis; RV, right ventricular; RV‐FAC, right ventricular fractional area change; and RVOT, right ventricular outflow tract.

*P* values from multivariable logistic regression (adjusting for age and sex).

*P* values from ordinal logistic regression (adjusting for age and sex).

![Comparison of RV peak longitudinal systolic strain and strain rate across quartiles of 5‐year rate of change in PSAX RVOT, PLAX RVOT, and RV‐FAC.\
The distribution of RV peak longitudinal systolic strain on baseline echocardiography is compared across patients, arranged by 5‐year quartile rate of change of each structural marker. PLAX indicates parasternal long axis; PSAX, parasternal short axis; RV, right ventricular; RV‐FAC, right ventricular fractional area change; and RVOT, right ventricular outflow tract.](JAH3-9-e015016-g003){#jah35005-fig-0003}

We further defined an abnormal RV peak longitudinal systolic strain as being more positive (greater) than −20%. There were 24 patients (60%) with abnormal RV strain at baseline. These patients were at substantially greater risk of structural progression than those with a normal baseline RV strain: 18 times higher risk of RVOT PSAX progression (odds ratio: 18.4; 95% CI, 2.7--125.8; *P*=0.003) adjusting for age and sex and 3.7 times higher risk of RVOT PLAX progression (odds ratio: 3.65; 95% CI, 0.60--22.4; *P*=0.161).

Discussion {#jah35005-sec-0016}
==========

In this study, we evaluated 2‐dimensional echocardiographic RV strain as a predictor of structural disease progression in ARVC. This study has several notable findings. First, our results indicate that many patients exhibited progression in RVOT dimensions (60% for PSAX and 67% for PLAX) and less so for RV‐FAC during the follow‐up period. This finding is expected given that ARVC is a progressive disease and because similar findings have been seen in prior studies that have evaluated for progression on serial echocardiograms.[11](#jah35005-bib-0011){ref-type="ref"}, [26](#jah35005-bib-0026){ref-type="ref"}, [27](#jah35005-bib-0027){ref-type="ref"} Mast et al[11](#jah35005-bib-0011){ref-type="ref"} reported progression of all 3 measures (PSAX RVOT, PLAX RVOT, and RV‐FAC) in two‐thirds of their study population over a mean follow‐up time of 6.4 years, and this result was reproduced in our study.

Our results also indicate that worse RV free‐wall peak longitudinal systolic strain and strain rate are associated with increases in RVOT size, as obtained from PSAX and PLAX views. Specifically, when baseline strain and strain rate were compared for patients who demonstrated structural progression and those who did not, worse strain and strain rate were observed among the progressors. Higher quartiles of 5‐year RV structural progression (by both PSAX RVOT and PLAX RVOT) were associated with diminished RV free‐wall strain and strain rate at baseline (Table [3](#jah35005-tbl-0003){ref-type="table"}). Furthermore, patients with more abnormal RV strain (greater than −20%) had an 18‐fold risk (*P*=0.002) of progression in PSAX RVOT. Thus, RV free‐wall strain and strain rate appear to be predictive of structural progression of disease in patients with ARVC, and patients with relatively normal baseline values progressed slowly, whereas those with abnormal values progressed more rapidly. These measures may have important clinical utility because structural changes and progression are associated with arrhythmic events and development of heart failure.[21](#jah35005-bib-0021){ref-type="ref"}, [28](#jah35005-bib-0028){ref-type="ref"}, [29](#jah35005-bib-0029){ref-type="ref"}

Regarding measurement of RVOT, prior studies have shown that RVOT measures by echo are reproducible and correlate with cardiac magnetic resonance imaging measures. One study reported high reproducibility, with interclass correlation values \>0.91 for inter‐ and intraobserver correlation of 2‐dimensional RVOT measurements on echo.[30](#jah35005-bib-0030){ref-type="ref"} In addition, RVOT dimension on transthoracic echocardiogram exhibited good correlation with the same measure on cardiac magnetic resonance (*r*=0.87; 95% CI, 0.75--0.93; *P\<*0.0001) and good absolute agreement with a mean difference of 0.2 mm between the 2 imaging modalities.[30](#jah35005-bib-0030){ref-type="ref"} This metric was used in our study and was utilized by the Heart Rhythm Society 2010 TFC in the diagnosis of ARVC. Another study[11](#jah35005-bib-0011){ref-type="ref"} reported a 2‐mm increase in RVOT dimension over time in a population of ARVC patients and was found to be significant, similar to our current findings. Based on the reproducibility of RVOT measurements and findings in prior studies, changes in RVOT size in this study of 2.3 and 3.2 mm on PSAX and PLAX views, respectively, are appropriately significant, and they correspond to relative changes of ≈6.3% and 8.6% from baseline to follow‐up.

It should be noted that patients who progressed by RVOT PSAX had lower baseline RV‐FAC, larger RV basal diameters, and greater fulfillment of major structural criteria by echocardiography at baseline compared with patients who did not progress by RVOT PSAX (Table [2](#jah35005-tbl-0002){ref-type="table"}). These findings are consistent with the notion that ARVC is a progressive disease; patients who exhibited progression tended to have greater evidence of disease at baseline. In addition, these findings were not observed among progressors by RVOT PLAX. It is possible that variability in imaging technique is responsible for this discrepancy. However, it also suggests that RV strain and strain rate, in addition to other structural markers of disease, can be used to predict structural progression. Patients who progressed by RVOT PSAX tended to be male; however, the implications of this finding are unclear and perhaps incidental, as this association was not seen for RVOT PLAX and RV‐FAC. Patients who progressed by RV‐FAC tended to have larger RV‐FAC at baseline, perhaps reflecting a larger "window" for decrease in RV function with higher RV‐FAC at baseline.

In a prior study by Mast et al,[22](#jah35005-bib-0022){ref-type="ref"} subtricuspid RV deformation was evaluated in first‐degree relatives of patients with ARVC, using criteria that incorporated strain. The authors concluded that abnormal RV deformation seemed to precede established signs of ARVC. However, the study performed by Mast et al[22](#jah35005-bib-0022){ref-type="ref"} utilized prespecified deformation patterns to predict disease progression, whereas our study evaluated RV free‐wall peak longitudinal systolic strain and strain rate. Our structural predictors for disease progression are related to the described deformation patterns but are arguably simpler to implement. Furthermore, the patient population in the study by Mast et al[22](#jah35005-bib-0022){ref-type="ref"} consisted of first‐degree relatives of patients with ARVC and excluded patients who fulfilled TFC for structural abnormalities. In contrast, our study evaluated patients who carried diagnoses of definite ARVC regardless of criteria fulfilled. Thus, our study expands the patient population in which strain imaging may be useful.

Speckle‐tracking strain can also assess ventricular contraction homogeneity using mechanical dispersion, which is defined as the standard deviation of the time from the Q/R on ECG to peak negative longitudinal strain for all RV or LV segments. Prior studies have evaluated RV and LV mechanical dispersion, in addition to RV strain, to predict arrhythmias in ARVC and differentiate early ARVC from RVOT--ventricular tachycardia patients.[31](#jah35005-bib-0031){ref-type="ref"}, [32](#jah35005-bib-0032){ref-type="ref"}, [33](#jah35005-bib-0033){ref-type="ref"} Leren et al[32](#jah35005-bib-0032){ref-type="ref"} found RV mechanical dispersion to be a marker of prior arrhythmic events in patients with early ARVC, but the authors also identified an association between diminished RV global longitudinal strain and arrhythmia events in a broader population that included patients with definite ARVC. Lie et al[33](#jah35005-bib-0033){ref-type="ref"} also found an association between RV longitudinal strain and life‐threatening ventricular arrhythmias but identified a stronger relationship using LV mechanical dispersion. In contrast to these studies, our study validates the utility of strain techniques in the definite ARVC population and demonstrates the ability of strain to predict other markers of ARVC severity, namely, structural progression. In addition, compared with mechanical dispersion, RV free‐wall strain is more widely available and less technically demanding to assess, making it more suitable for serial measurements over time to assess structural progression.

Results for RV‐FAC disagree with our hypothesis; however, in our study population, the RV‐FAC remained relatively stable during the follow‐up period, with very few patients progressing. Saguner et al[26](#jah35005-bib-0026){ref-type="ref"} found that reduced FAC was highly predictive of major adverse cardiovascular events in patients with ARVC. However, they also reported no association between an impaired tricuspid annular plane systolic excursion and subtricuspid regional wall motion abnormalities. Consequently, it is possible that strain and strain rate are more predictive of changes in the RVOT dimensions for patients with ARVC than for overall RV systolic function. Findings for RV‐FAC may also have been limited by a relatively small patient population. In addition, the technical challenges of accurately determining RV‐FAC on 2‐dimensional echocardiographic imaging may have led to variability in assessment of RV function.

Limitations {#jah35005-sec-0017}
-----------

This study has several limitations. First, it was a retrospective study from a single referral center with variable follow‐up periods and relatively small sample size; however, because of the rare nature of ARVC, the study is still one of the largest of its kind. The measurement of strain and strain rate can be inconsistent depending on the user, image quality, software, or vendor of the echocardiography system. This is particularly true for the right ventricle, which remains challenging to assess quantitatively by echocardiography. However, we mitigated this by having only a single operator evaluate RV strain under the same software/hardware conditions. Furthermore, the operator was blinded to clinical data during analysis. It should also be noted that strain and wall dimension are related. However, apart from comparing against changes in RV‐FAC, RV free‐wall strain was used to identify changes in the RVOT, an anatomically separated location from where strain was measured. Last, echocardiography may be less sensitive than magnetic resonance imaging for determining structural progression of disease, given the ability of magnetic resonance imaging to identify segmental RV dilatation or hypokinesis with higher resolution.[34](#jah35005-bib-0034){ref-type="ref"} Nevertheless, echocardiography is more widely available clinically, particularly for ARVC patients, the majority of whom have defibrillators requiring special magnetic resonance imaging protocols.

Conclusions {#jah35005-sec-0018}
===========

Our study recognizes echocardiographic strain as a useful technique to predict structural progression of disease in ARVC. These findings suggest that echocardiographic strain and strain rate could be useful in identification of patients at risk of disease progression who may require closer follow‐up and treatment.
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